Cargando…
Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up
OBJECTIVES: To investigate prevalence of iatrogenic atrial septal defects (iASDs) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) with the MitraClip in the long-term follow-up. BACKGROUND: MV TEER requires transseptal puncture using a large 22 F sheath. Prevalence, impact and haemod...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549666/ https://www.ncbi.nlm.nih.gov/pubmed/34702777 http://dx.doi.org/10.1136/openhrt-2021-001732 |
_version_ | 1784590816077938688 |
---|---|
author | Paukovitsch, Michael Schneider, Leonhard Moritz Reichart, Christine Nita, Nicoleta Rottbauer, Wolfgang Keßler, Mirjam Markovic, Sinisa |
author_facet | Paukovitsch, Michael Schneider, Leonhard Moritz Reichart, Christine Nita, Nicoleta Rottbauer, Wolfgang Keßler, Mirjam Markovic, Sinisa |
author_sort | Paukovitsch, Michael |
collection | PubMed |
description | OBJECTIVES: To investigate prevalence of iatrogenic atrial septal defects (iASDs) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) with the MitraClip in the long-term follow-up. BACKGROUND: MV TEER requires transseptal puncture using a large 22 F sheath. Prevalence, impact and haemodynamic effects of these iASDs remain unknown in the long-term follow-up. METHODS: This prospective study enrolled patients who had undergone first-time TEER at our university hospital between January 2017 and June 2018 for a clinical long-term follow-up study. Prevalence of iASD was investigated 12 months post-TEER using transoesophageal echocardiography (TEE). Study protocol further consisted of transthoracic echocardiography (TTE) and exercise testing. Incidence of all-cause death was compared 12 months post-TEE follow-up. This study was approved by local ethics committee. RESULTS: 48 patients participated in clinical follow-up examinations. Median time between TEER and clinical follow-up examination (TEE, TTE, exercise testing) was 19.5 (IQR: 7.0) months after TEER. Persistent iASD was found in 41.7% of patients. TEER was found to be equally effective in reducing MR and clinical symptoms in both groups at baseline as well as follow-up. Procedural fluoroscopy and device times were significantly longer in the iASD group. MR reduction and functional status (New York Heart Association Class, 6 Minute Walking Test distance) were similar in both groups. Nevertheless, a significant decrease in systolic pulmonary artery pressure (sPAP) and significantly smaller atrial diameters were observed in patients with iASD at follow-up. CONCLUSION: Prevalence of iASDs after TEER in long-term follow-up was about 41%. Although a significant reduction of sPAP and better left atrial reverse remodelling were accomplished in patients with iASD, clinical impact appears low. Manipulation at the atrial septum might play a key role in creating persisting iASD. |
format | Online Article Text |
id | pubmed-8549666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-85496662021-10-29 Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up Paukovitsch, Michael Schneider, Leonhard Moritz Reichart, Christine Nita, Nicoleta Rottbauer, Wolfgang Keßler, Mirjam Markovic, Sinisa Open Heart Interventional Cardiology OBJECTIVES: To investigate prevalence of iatrogenic atrial septal defects (iASDs) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) with the MitraClip in the long-term follow-up. BACKGROUND: MV TEER requires transseptal puncture using a large 22 F sheath. Prevalence, impact and haemodynamic effects of these iASDs remain unknown in the long-term follow-up. METHODS: This prospective study enrolled patients who had undergone first-time TEER at our university hospital between January 2017 and June 2018 for a clinical long-term follow-up study. Prevalence of iASD was investigated 12 months post-TEER using transoesophageal echocardiography (TEE). Study protocol further consisted of transthoracic echocardiography (TTE) and exercise testing. Incidence of all-cause death was compared 12 months post-TEE follow-up. This study was approved by local ethics committee. RESULTS: 48 patients participated in clinical follow-up examinations. Median time between TEER and clinical follow-up examination (TEE, TTE, exercise testing) was 19.5 (IQR: 7.0) months after TEER. Persistent iASD was found in 41.7% of patients. TEER was found to be equally effective in reducing MR and clinical symptoms in both groups at baseline as well as follow-up. Procedural fluoroscopy and device times were significantly longer in the iASD group. MR reduction and functional status (New York Heart Association Class, 6 Minute Walking Test distance) were similar in both groups. Nevertheless, a significant decrease in systolic pulmonary artery pressure (sPAP) and significantly smaller atrial diameters were observed in patients with iASD at follow-up. CONCLUSION: Prevalence of iASDs after TEER in long-term follow-up was about 41%. Although a significant reduction of sPAP and better left atrial reverse remodelling were accomplished in patients with iASD, clinical impact appears low. Manipulation at the atrial septum might play a key role in creating persisting iASD. BMJ Publishing Group 2021-10-26 /pmc/articles/PMC8549666/ /pubmed/34702777 http://dx.doi.org/10.1136/openhrt-2021-001732 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Interventional Cardiology Paukovitsch, Michael Schneider, Leonhard Moritz Reichart, Christine Nita, Nicoleta Rottbauer, Wolfgang Keßler, Mirjam Markovic, Sinisa Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title | Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title_full | Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title_fullStr | Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title_full_unstemmed | Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title_short | Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up |
title_sort | prevalence of iatrogenic atrial septal defects (iasd) after mitral valve (mv) transcatheter edge-to-edge repair (teer) in the long-term follow-up |
topic | Interventional Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549666/ https://www.ncbi.nlm.nih.gov/pubmed/34702777 http://dx.doi.org/10.1136/openhrt-2021-001732 |
work_keys_str_mv | AT paukovitschmichael prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT schneiderleonhardmoritz prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT reichartchristine prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT nitanicoleta prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT rottbauerwolfgang prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT keßlermirjam prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup AT markovicsinisa prevalenceofiatrogenicatrialseptaldefectsiasdaftermitralvalvemvtranscatheteredgetoedgerepairteerinthelongtermfollowup |